Premium
Gastrointestinal stromal tumors (GISTs): a review
Author(s) -
STEIGEN SONJA E.,
EIDE TOR J.
Publication year - 2009
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/j.1600-0463.2008.00020.x
Subject(s) - gist , interstitial cell of cajal , gastrointestinal tract , stromal cell , medicine , mesenchymal stem cell , pathology , stromal tumor , cancer research , neoplasm , tyrosine kinase inhibitor , imatinib , tyrosine kinase , targeted therapy , imatinib mesylate , therapeutic modalities , cancer , immunohistochemistry , receptor , myeloid leukemia
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal neoplasms in the gastrointestinal tract, which, over the last 10 years, have emerged from a poorly understood neoplasm to a well‐defined tumor entity exhibiting particular molecular abnormalities and for which promising novel treatment modalities have been developed. GISTs probably arise from the precursor cell of the interstitial cell of Cajal, express KIT tyrosine kinase in most of the cases and harbor mutations of importance for individualized treatment. The molecular targets for therapeutic interventions are not only of importance for the treatment of GIST patients but also useful for in the development of novel drug modalities and new strategies in basic cancer therapy.